EMA accepts fidaxomicin MAA

The European Medicines Agency (EMA) accepted for review an MAA from Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) for fidaxomicin to treat and prevent recurrence of Clostridium difficile infection. Optimer said it has retained JPMorgan to assist in partnering the product in Europe. ...